September 7, 2011
Orphazyme raises a $20,000,000 series A round from Aescap Venture.
Documentaries, videos and podcasts
Vanessa Doctor, RN
June 29, 2021
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
June 29, 2021
Orphazyme is taking the ax to most of its workforce after its beleaguered single asset has been hit by rejections and serial flops in the clinic.
June 18, 2021
The FDA said that the drug, which has been studied and submitted for NPC indication, needs further data to support its use in this rare, progressive genetic disorder.
June 18, 2021
The FDA has rejected Orphazyme's Niemann-Pick disease type C drug candidate arimoclomol. Orphazyme said the agency wants additional data on the benefits and risks of the heat shock protein amplifier, leading it to cut costs as it figures out its next steps.
June 14, 2021
The month of June continues to be busy for the U.S. Food and Drug Administration. There are three PDUFA dates on the calendar for this week. Here's a look.
June 11, 2021
Orphazyme AS, which develops therapies to treat genetic disorders, says it has no idea why its American depositary shares surged overnight
May 18, 2021
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH). Such investors are...
March 29, 2021
Orphazyme saw its stock sink more than 30% in Europe Monday morning after it failed to to hit any of the endpoints in a phase 2/3 trial.
November 11, 2020
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C - read this article along with other careers information, tips and advice on BioSpace
May 26, 2020
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development of arimoclomol for the t
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.